Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

NCT01952574 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

483

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: Erenumab
DRUG: Placebo
DRUG: Erenumab PFS
DRUG: Erenumab AI/Pen

Sponsor

Amgen